Telix Pharmaceuticals (TLPPF) Total Liabilities (2023 - 2026)

Telix Pharmaceuticals (TLPPF) has reported Total Liabilities for 4 consecutive years, with $874.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Liabilities changed N/A year-over-year to $874.2 million in Q2 2026; TTM through Jun 2026 was $874.2 million, a N/A change from a year earlier, with the FY2025 full-year figure at $748.6 million, up 27.44% from the prior year.
• Total Liabilities was $874.2 million for Q2 2026 at Telix Pharmaceuticals, up from $748.6 million in the prior quarter.
• Over five years, Total Liabilities peaked at $874.2 million in Q2 2026 and troughed at $167.3 million in Q4 2023.
• A 4-year average of $602.6 million and a median of $684.4 million in 2025 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities surged 270.57% in 2024 and gained 20.73% in 2025, its largest moves.
• Over 4 years, Total Liabilities stood at $167.3 million in 2023, then jumped by 270.57% to $620.1 million in 2024, then gained by 20.73% to $748.6 million in 2025, then rose by 16.77% to $874.2 million in 2026.
• The last three Total Liabilities figures came in at $874.2 million (Q2 2026), $748.6 million (Q4 2025), and $620.1 million (Q4 2024), per Business Quant data.